Healthcare / Diagnostics & ResearchBSE
$539.05
-2.05 (-0.38%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 22% · confianza 25%
FCF escenarios
weak_data · normalized FCF $2.0B · quality 86.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
63/100
B
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$111.8B
P/E
58.6x
↑EV/EBITDA
27.2x
↑ROE
12.6%
↑Gross Margin
78.9%
↑Debt/Equity
0.15
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2023–2026 · 3 años de histórico normalizado
Revenue CAGR
+12.8%
FCF CAGR
+15.5%
FCF margin
18.2%
FCF / Net income
1.58x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $16.46B · net income $1.90B · FCF $3.00B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $16.46B | $16.46B | $13.31B | $12.08B | $11.48B |
| Net Income | $1.90B | $1.90B | $1.45B | $1.28B | $1.43B |
| EBITDA | $4.17B | $4.17B | $3.18B | $2.92B | $3.04B |
| EPS | — | — | 7.04 | 6.22 | 6.95 |
| Gross Margin | 78.9% | 78.9% | 79.1% | 78.4% | 77.0% |
| Operating Margin | 16.2% | 16.2% | 14.6% | 16.8% | 18.2% |
| Net Margin | 11.5% | 11.5% | 10.9% | 10.6% | 12.4% |
| Balance Sheet | |||||
| Debt/Equity | 0.15 | 0.15 | 0.15 | 0.18 | 0.27 |
| Current Ratio | 1.40 | 1.40 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $3.00B | $3.00B | $1.94B | $2.00B | $1.94B |
| Returns | |||||
| ROE | 12.6% | 12.6% | 10.9% | 11.7% | 14.5% |
| Valuation | |||||
| P/E | 58.59 | 58.59 | 55.05 | 68.95 | 44.59 |
| EV/EBITDA | 27.20 | 27.20 | 25.60 | 30.67 | 21.64 |
| P/B | 7.39 | 7.39 | 6.00 | 8.04 | 6.45 |
| Growth & Yield | |||||
| Revenue Growth | 23.6% | 23.6% | 10.2% | 5.2% | — |
| EPS Growth | — | — | 13.2% | -10.6% | — |
| Dividend Yield | 0.4% | 0.4% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+29.7%
Start / end P/E
n/dx → n/dx
EPS bridge
7.04 → n/d
Residual
+29.4%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.